Thermo Fisher Scientific Completes $2.2 Billion Registered Public Offering of Senior Notes

Thermo Fisher Scientific Completes $2.2 Billion Registered Public Offering of Senior Notes

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.

WilmerHale represented Thermo Fisher Scientific Inc., a multinational biotechnology product development company, in its public offering of $1.1 billion aggregate principal amount of 4.133% Senior Notes due 2025 and $1.1 billion aggregate principal amount of 4.497% Senior Notes due 2030. Both series of notes priced at 100% of principal. The net proceeds of the offering will be used to pay a portion of the purchase price of the previously announced acquisition of QIAGEN N.V and for general corporate purposes. The offering priced on March 23, 2020 and closed on March 25, 2020.

The team consisted of Erika Robinson, Justin Ochs, Julie Hogan Rodgers, Alan Wilson and Jenny Moore.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel